Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Bristol-Myers Squibb calls early end to apixaban trial

Bristol-Myers Squibb calls early end to apixaban trial

14th June 2010

Bristol-Myers Squibb has ended its clinical trial of the atrial fibrillation treatment apixaban, after the drug demonstrated its efficacy earlier than expected.

The company has reached an agreement with collaborative partner Pfizer to halt the phase III Averroes trial in response to evidence from an independent data monitoring committee.

This data illustrated that apixaban performed better than aspirin in terms of reducing strokes and systemic embolisms among atrial fibrillation patients unable to undergo vitamin K antagonist therapy.

Following this announcement, the Population Health Research Institute (PHRI) at McMaster University and at Hamilton Health Sciences, which coordinated the study, will be evaluating and publishing the final data.

Patients will also be given the chance to start treatment with apixaban in an open-label extension.

Last week, Bristol-Myers Squibb published new clinical trial data for leukaemia drug Sprycel, which illustrated the advantages it offers compared to Gleevec.

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.